专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012037196A1 METHODS OF TREATING AUTOIMMUNE DISEASES WITH ANTI-FCERI ANTIBODIES 审中-公开
标题翻译：用抗FCERI抗体治疗自身免疫性疾病的方法
公开(公告)号：WO2012037196A1
公开(公告)日：2012-03-22
申请号：PCT/US2011/051518
申请日：2011-09-14
申请人： THE HENRY M. JACKSON FOUNDATION , MITRE, Edward, E. , HÜBNER, Marc, P.
发明人： MITRE, Edward, E. , HÜBNER, Marc, P.
IPC分类号： G01N33/564 , G01N33/00 , C12Q1/02 , C07K16/00
CPC分类号： A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K16/283 , Y10S424/805 , Y10S424/81
摘要： Methods of using anti-FceRI or anti-lgE antibodies for treating an autoimmune disease are disclosed. Also disclosed is a composition comprising an anti-FceRI antibody or anti-IgE antibody for use in treating an autoimmune disease. Also disclosed are non-antibody compounds that specifically activate basophils and/or'mast cells, either by cross-linking IgE or FceRI, or by activating the cells through an FceRI-independent pathway and methods of using the same to treat autoimmune diseases.
摘要翻译：公开了使用抗FceRI或抗-IgE抗体治疗自身免疫疾病的方法。还公开了包含用于治疗自身免疫性疾病的抗FceRI抗体或抗IgE抗体的组合物。还公开了通过交联IgE或FceRI特异性活化嗜碱性粒细胞和/或“哺乳细胞”的非抗体化合物，或通过不依赖FceRI的途径激活细胞以及使用其来治疗自身免疫性疾病的方法。

2. 发明申请

WO2010145849A2 DRUG DELIVERY SYSTEMS 审中-公开
标题翻译：药物递送系统
公开(公告)号：WO2010145849A2
公开(公告)日：2010-12-23
申请号：PCT/EP2010/003783
申请日：2010-06-07
申请人： MAGNANI, Mauro , ROSSI, Luigia , BIAGIOTTI, Sara , BIANCHI, Marzia
发明人： MAGNANI, Mauro , ROSSI, Luigia , BIAGIOTTI, Sara , BIANCHI, Marzia
IPC分类号： A61K9/50
CPC分类号： C12N5/0641 , A61K31/535 , A61K35/18 , A61K38/13 , A61K47/42 , A61K47/6901 , Y10S424/81 , Y10S514/855
摘要： Red blood cells can be used as effective drug delivery systems when they contain proteins that do not readily diffuse out and which form affinity complexes with the desired drug.
摘要翻译：当红细胞含有不容易扩散的蛋白质并与所需药物形成亲和复合物时，红细胞可用作有效的药物递送系统。

3. 发明申请

WO2004111608A8 METHOD OF ALTERING THE BINDING SPECIFICITY OF PLASMA PROTEINS BY OXIDATION-REDUCTION REACTIONS 审中-公开
标题翻译：通过氧化还原反应改变等离子体蛋白的结合特性的方法
公开(公告)号：WO2004111608A8
公开(公告)日：2005-12-29
申请号：PCT/US2004017889
申请日：2004-06-09
申请人： MCINTYRE JOHN A
发明人： MCINTYRE JOHN A
IPC分类号： A61K39/395 , B01D57/02 , C07K1/113 , C07K1/24 , C07K1/26 , C07K14/475 , C07K14/765 , C07K16/00 , C07K16/18 , C12N15/01 , G01N20060101 , G01N33/53 , G01N33/561 , G01N33/564 , A61K1/38
CPC分类号： C07K16/00 , C07K16/18 , C07K2317/21 , G01N33/5306 , G01N33/5375 , G01N33/564 , G01N33/6854 , Y10S424/81 , Y10S436/825 , Y10S530/868
摘要： The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium it altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
摘要翻译：悬浮或溶解在液体培养基中的至少一种血浆蛋白的结合特异性通过将蛋白质暴露于氧化剂或足以改变其结合特异性的电流而改变。通过氧化蛋白质以改变其结合特异性，可以从血液或血液制品或提取物中回收诸如自身抗体的掩蔽蛋白质。

4. 发明申请

WO03024993A3 MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS 审中-公开
标题翻译：用ELISA测定法测定循环的治疗性抗体，抗原和抗原/抗体复合物
公开(公告)号：WO03024993A3
公开(公告)日：2003-10-16
申请号：PCT/US0230142
申请日：2002-09-20
申请人： UNIV TEXAS , ALBITAR MAHER , KEATING MICHAEL J , MANSHOURI TAGHI
发明人： ALBITAR MAHER , KEATING MICHAEL J , MANSHOURI TAGHI
IPC分类号： G01N33/53 , A61K39/395 , A61P5/14 , A61P13/08 , A61P13/10 , A61P19/02 , A61P25/00 , A61P27/02 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , G01N33/543 , G01N33/564 , G01N33/574 , G01N33/577 , G01N33/566
CPC分类号： G01N33/6872 , C07K16/2887 , C07K2317/24 , C07K2317/76 , G01N33/564 , G01N33/57407 , G01N33/57492 , G01N33/6893 , G01N2333/70596 , G01N2800/52 , Y10S424/81 , Y10S436/809 , Y10T436/106664 , Y10T436/107497
摘要： The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
摘要翻译：本发明涉及免疫学和过度增殖性疾病领域。更具体地说，本发明涉及检测和监测治疗性抗体的方法：抗原复合物，可溶性抗原和可溶性治疗性抗体，其中患者经历至少一个免疫治疗过程。另外，可以测量治疗性抗体：抗原复合物，可溶性抗原或可溶性治疗性抗体的水平并用于分期或监测过度增殖性疾病。

5. 发明申请

WO2003009808A2 METHODS, COMPOSITIONS AND KITS RELATING TO CHITINASES AND CHITINASE-LIKE MOLECULES AND INFLAMMATORY DISEASE 审中-公开
标题翻译：方法，组合物和与CH SE KE KE KE AND AND AND ASE ASE ASE ASE ASE ASE ASE ASE ASE ASE ASE ASE ASE ASE
公开(公告)号：WO2003009808A2
公开(公告)日：2003-02-06
申请号：PCT/US2002/023516
申请日：2002-07-23
申请人： YALE UNIVERSITY , ELIAS, Jack, A. , ZHU, Zhou
发明人： ELIAS, Jack, A. , ZHU, Zhou
IPC分类号： A61K
CPC分类号： A61K39/395 , A61K31/00 , A61K31/70 , A61K38/12 , C07K16/18 , C07K16/40 , C07K2317/77 , C12N9/2442 , C12Y302/01014 , Y10S424/81 , Y10S530/868
摘要： The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of the inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.
摘要翻译：本发明包括与抑制几丁质酶样分子有关的炎症性疾病（例如哮喘，COPD，炎性肠病，特应性皮炎，过敏，过敏性鼻炎，硬皮病等）的组合物和方法。本发明还包括鉴定用于治疗炎性疾病的新化合物的方法，包括但不限于哮喘，COPD等。这是因为本发明首次证明IL-13和几丁质酶样分子的表达介导和/或与炎性疾病相关，并且抑制几丁质酶样分子治疗甚至预防，这种病。因此，本发明涉及抑制几丁质酶样分子治疗和预防炎性疾病的新发现。

6. 发明申请

WO9963101A9 TRANSFECTED CELLS AND METHODS FOR TREATING DIABETES 审中-公开
标题翻译：转基因细胞和治疗糖尿病的方法
公开(公告)号：WO9963101A9
公开(公告)日：2000-03-30
申请号：PCT/US9911970
申请日：1999-06-01
申请人： UNIV WASHINGTON , OSBORNE WILLIAM R A , RAMESH NAGARAJAN
发明人： OSBORNE WILLIAM R A , RAMESH NAGARAJAN
IPC分类号： A61K35/12 , A61K38/28 , A61K48/00 , C12N5/071 , C12N5/22 , A61F2/02 , C12N5/10
CPC分类号： C12N5/069 , A61K35/12 , A61K38/28 , A61K48/00 , C12N2510/02 , Y10S424/81 , Y10S514/866
摘要： The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsuling cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.
摘要翻译：本发明提供了一种分离的细胞群，其含有编码胰岛素原的可表达核酸，该核酸含有胰岛素原裂解位点和编码能够切割前胰岛素切割位点以产生胰岛素的蛋白酶的葡萄糖调节的可表达核酸。本发明还提供了进一步表达己糖胺合成途径酶的分离的细胞群。本发明另外提供含有编码胰岛素原的可表达核酸的载体，所述胰岛素原含有胰岛素原裂解位点和编码能够切割胰岛素原裂解位点以产生胰岛素的蛋白酶的葡萄糖调节的可表达核酸。本发明进一步提供了一种通过植入个体共表达含有胰岛素原裂解位点的胰岛素原和能切割胰岛素原裂解位点以产生胰岛素的葡萄糖调节蛋白酶的细胞来治疗或预防糖尿病的方法。

7. 发明申请

WO00005250A1 TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES 审中-公开
标题翻译：用共聚物1和相关共聚物和肽处理自动调节条件
公开(公告)号：WO00005250A1
公开(公告)日：2000-02-03
申请号：PCT/US1999/016747
申请日：1999-07-23
IPC分类号： A61K38/00 , A61K38/16 , A61K39/00 , A61L27/22 , C07K5/11 , C07K7/06 , C07K7/08 , C07K14/00 , C07K7/00
CPC分类号： G01N33/6842 , A61K38/16 , A61K39/0008 , A61L27/22 , A61L27/227 , C07K5/1019 , C07K7/06 , C07K7/08 , C07K14/001 , Y10S424/81 , Y10S530/806
摘要： The present invention is directed to polypeptides and peptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Morever, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides or peptides to the mammal.
摘要翻译：本发明涉及含有以线性阵列随机连接的至少三个氨基酸的多肽和肽; 其中所述三个氨基酸中的至少一个是芳族氨基酸，所述三个氨基酸中的至少一个是带电荷的氨基酸，并且至少一个氨基酸是脂族氨基酸。在优选的实施方案中，多肽含有三个或四个以下氨基酸：酪氨酸，丙氨酸，谷氨酸或赖氨酸。根据本发明，本发明的多肽与抗原呈递细胞，纯化的人淋巴细胞抗原（HLA）和/或共聚物1-特异性T细胞结合。更重要的是，根据本发明，这些多肽可以配制成用于治疗自身免疫疾病的药物组合物。本发明进一步考虑通过向哺乳动物施用药学有效量的本发明多肽或肽中的任何一种来治疗哺乳动物自身免疫性疾病的方法。

8. 发明申请

WO9901556A2 IMPROVED ANTI-IgE ANTIBODIES AND METHOD OF IMPROVING POLYPEPTIDES 审中-公开
标题翻译：改进的抗IgE抗体和改进多肽的方法
公开(公告)号：WO9901556A2
公开(公告)日：1999-01-14
申请号：PCT/US9813410
申请日：1998-06-30
申请人： GENENTECH INC
发明人： LOWMAN HENRY B , PRESTA LEONARD G , JARDIEU PAULA M , LOWE JOHN
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P37/00 , A61P37/06 , A61P37/08 , A61P43/00 , C07K16/00 , C07K16/42 , C12N15/13 , C12P21/08
CPC分类号： C07K16/00 , A61K38/00 , C07K16/4291 , C07K2317/24 , Y10S424/81 , Y10S530/868
摘要： The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which are prone to isomerization; (2) the substitution of alternative residues and screening the resulting mutants for affinity against the target molecule. In a preferred embodiment, the method of substituting residues is affinity maturation with phage display (AMPD). In a further preferred embodiment the polypeptide is an antibody and the target molecule is an antigen. In a further preferred embodiment, the antibody is anti-IgE and the target molecule is IgE. In another embodiment, the invention relates to an anti-IgE antibody having improved affinity to IgE.
摘要翻译：本发明涉及通过步骤组合来调节多肽对靶分子的亲和力的方法，所述方法包括：（1）鉴定易于异构化的天冬氨酰残基; （2）替代残基的替换并筛选产生的突变体对靶分子的亲和力。在一个优选的实施方案中，取代残基的方法是用噬菌体展示（AMPD）进行亲和力成熟。在进一步优选的实施方案中，多肽是抗体并且靶分子是抗原。在进一步优选的实施方案中，抗体是抗IgE，靶分子是IgE。在另一个实施方案中，本发明涉及对IgE具有改善的亲和力的抗IgE抗体。

9. 发明申请

WO1998007436A1 TREATMENT OF AUTOIMMUNE DISEASES 审中-公开
标题翻译：治疗自身免疫性疾病
公开(公告)号：WO1998007436A1
公开(公告)日：1998-02-26
申请号：PCT/CA1997000564
申请日：1997-08-11
申请人： VASOGEN INC.
发明人： VASOGEN INC. , BOLTON, Anthony, E.
IPC分类号： A61K35/14
CPC分类号： A61M1/3681 , A61K33/40 , A61K35/14 , A61K41/0019 , A61M1/32 , A61M1/3683 , A61M2202/0216 , A61M2202/0275 , A61M2205/053 , Y10S424/81
摘要： An autoimmune vaccine is provided for administration to human patients to alleviate the symptoms of autoimmune diseases such as rheumatoid arthritis. The vaccine comprises an aliquot of the patient's blood, containing, inter alia , leukocytes having upregulated expression of various cell surface markers and lymphocytes containing decreased amounts of certain stress proteins. It is produced by subjecting the blood aliquot extracorporeally to certain stressors, namely oxidizing agents, UV radiation and elevated temperature.
摘要翻译：提供了一种自身免疫性疫苗，用于给予人类患者以减轻自身免疫疾病如类风湿性关节炎的症状。疫苗包含患者血液的等分试样，其中尤其含有具有上调表达各种细胞表面标志物的白细胞和含有减少量某些应激蛋白的淋巴细胞。它是通过将血液等分试样经受某些压力源，即氧化剂，紫外线辐射和升高的温度而产生的。

10. 发明申请

WO1997049809A1 POLYPEPTIDES CAPABLE OF FORMING ANTIGEN BINDING STRUCTURES WITH SPECIFICITY FOR THE RHESUS D ANTIGENS, THE DNA ENCODING THEM AND THE PROCESS FOR THEIR PREPARATION AND USE 审中-公开
标题翻译：能够形成针对RHESUS D抗原的特异性抗原结合结构的多核苷酸，编码它们的DNA及其制备和使用过程
公开(公告)号：WO1997049809A1
公开(公告)日：1997-12-31
申请号：PCT/EP1997003253
申请日：1997-06-20
申请人： ROTKREUZSTIFTUNG ZENTRALLABORATORIUM BLUTSPENDEDIENST SRK , MIESCHER, Sylvia , VOGEL, Monique , STADLER, Beda , MORELL, Andreas , IMBODEN, Martin , AMSTUTZ, Hanspeter
发明人： ROTKREUZSTIFTUNG ZENTRALLABORATORIUM BLUTSPENDEDIENST SRK
IPC分类号： C12N15/13
CPC分类号： G01N33/80 , A61K38/00 , A61K39/395 , C07K16/34 , C07K2317/55 , C07K2319/00 , Y10S424/80 , Y10S424/81 , Y10S530/868
摘要： Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the figures 1a to 16b. The obtained polypeptides, being Fab fragments, may be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be used for the preparation of complete recombinant Anti-Rhesus D antibodies. Useful in pharmaceutical and diagnostic compositions.
摘要翻译：能够形成针对恒河猴D抗原特异性的抗原结合结构的多肽包括图1a至16b所示的序列。获得的多肽，即Fab片段，可直接用作药物和诊断组合物中的活性成分。 Fab及其DNA序列也可用于制备完整的重组抗恒河猴D抗体。适用于制药和诊断组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式